LEUSTATIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Feb 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEUSTATIN is an injectable small-molecule chemotherapy approved in 1993 for hematologic malignancies. The drug is administered intravenously and represents a mature oncology asset with limited mechanism-of-action data available in this dataset. Patient outcomes and exact indications require access to full labeling.
LOE Approaching
As LOE approaches, commercial team focus will shift to lifecycle extension strategies, partnership models, or managed exit; anticipate smaller, specialized team composition focused on retention and compliance.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LEUSTATIN offers limited career growth opportunity given its LOE-approaching lifecycle and zero linked job postings. This role is best suited for professionals seeking stable, focused specialty oncology experience or preparing for post-launch product transitions and organizational restructuring.
Brand ManagerMedical Science Liaison
Worked on LEUSTATIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.